← Open Payments lookup

NPI 1710950720: Open Payments

NPI 1710950720. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,623 in 67 payments from 11 companies in 2025. Trend: 2023 $2,573 · 2024 $2,204 · 2025 $1,623

Food & beverage: $1,623
CompanyPaymentsAmount
Janssen Pharmaceuticals, Inc10$314
E.R. Squibb & Sons, L.L.C.13$305
Axsome Therapeutics, Inc.6$268
Takeda Pharmaceuticals U.S.A., Inc.14$219
Teva Pharmaceuticals USA, Inc.6$121
Vanda Pharmaceuticals Inc.5$120
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)4$78
Neurocrine BioSciences, Inc.4$78
Otsuka America Pharmaceutical, Inc.3$64
Otsuka Pharmaceutical Development & Commercialization, Inc.1$31

Products named: INVEGA SUSTENNA, COBENFY, Auvelity, TRINTELLIX, FANAPT, CAPLYTA, INGREZZA, UZEDY.